Titan Pharmaceuticals (NASDAQ:TTNP) posted its quarterly earnings results on Wednesday. The specialty pharmaceutical company reported ($0.34) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.26) by ($0.08), Morningstar.com reports. The company had revenue of $0.95 million during the quarter. Titan Pharmaceuticals had a negative net margin of 136.32% and a negative return on equity of 355.20%.

Shares of TTNP stock traded down $0.17 during trading hours on Thursday, reaching $1.54. The company had a trading volume of 3,734 shares, compared to its average volume of 955,499. The company has a quick ratio of 3.49, a current ratio of 3.85 and a debt-to-equity ratio of 0.55. The company has a market cap of $22.92 million, a P/E ratio of -1.97 and a beta of 0.67. Titan Pharmaceuticals has a 1-year low of $1.03 and a 1-year high of $6.90.

Separately, ValuEngine raised Titan Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, February 2nd.

Hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC raised its stake in Titan Pharmaceuticals by 256.0% during the 4th quarter. Geode Capital Management LLC now owns 341,474 shares of the specialty pharmaceutical company’s stock worth $76,000 after buying an additional 245,565 shares during the period. Virtu Financial LLC raised its stake in Titan Pharmaceuticals by 530.0% during the 4th quarter. Virtu Financial LLC now owns 236,182 shares of the specialty pharmaceutical company’s stock worth $53,000 after buying an additional 198,693 shares during the period. Finally, Vanguard Group Inc raised its stake in Titan Pharmaceuticals by 12.7% during the 3rd quarter. Vanguard Group Inc now owns 432,337 shares of the specialty pharmaceutical company’s stock worth $90,000 after buying an additional 48,760 shares during the period. 23.94% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Titan Pharmaceuticals (TTNP) Posts Earnings Results, Misses Estimates By $0.08 EPS” was first reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://theolympiareport.com/2019/05/16/titan-pharmaceuticals-ttnp-posts-earnings-results-misses-estimates-by-0-08-eps.html.

Titan Pharmaceuticals Company Profile

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on treatments for chronic diseases. The company offers Probuphine, a product candidate for maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment.

See Also: What is the 52-week high/low?

Earnings History for Titan Pharmaceuticals (NASDAQ:TTNP)

Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.